Clinical Trial Update: Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating KN019 for rheumatoid arthritis with inadequate response to methotrexate, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• KN019

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED